Nonetheless, the higher residual expression of CD20 in ADPGK KO cells is important in the light of using chemotherapeutics such as Rituximab53 which depend on binding to CD20 and might also prove useful in lymphomas exhibiting resistance to this drug via shedding off the drug-CD20 complex. This evidence concerns the gene ADPGK and lymphoma.